Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 15/20 | 0.47 |
| ▸ | CHRM4 | P08173 | 15/20 | 0.47 |
| ▸ | CHRM3 | P20309 | 15/20 | 0.47 |
| ▸ | CHRM1 | P11229 | 14/20 | 0.47 |
| ▸ | CHRM5 | P08912 | 12/20 | 0.44 |
| ▸ | DPP4 | P27487 | 3/20 | 0.41 |
| ▸ | DPP8 | Q6V1X1 | 3/20 | 0.41 |
| ▸ | DPP9 | Q86TI2 | 3/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29816390 | 1.00 | CHRM2 (0.47) | CHRM2CHRM4CHRM3CHRM1CHRM5 | |
| SCHEMBL31497251 | 1.00 | CHRM2 (0.47) | CHRM2CHRM4CHRM3CHRM1CHRM5 | |
| SCHEMBL29411140 | 0.90 | DPP4 (0.42) | CHRM2CHRM4CHRM3CHRM1DPP4 | |
| SCHEMBL29816362 | 0.89 | CHRM2 (0.40) | CHRM2CHRM4CHRM3CHRM1CHRM5 | |
| SCHEMBL30785842 | 0.89 | CHRM2 (0.40) | CHRM2CHRM4CHRM3CHRM1CHRM5 | |
| SCHEMBL30785872 | 0.89 | CHRM2 (0.40) | CHRM2CHRM4CHRM3CHRM1CHRM5 | |
| SCHEMBL30785844 | 0.89 | CHRM2 (0.40) | CHRM2CHRM4CHRM3CHRM1CHRM5 | |
| SCHEMBL30785834 | 0.89 | CHRM2 (0.40) | CHRM2CHRM4CHRM3CHRM1CHRM5 | |
| SCHEMBL30785836 | 0.89 | CHRM2 (0.40) | CHRM2CHRM4CHRM3CHRM1CHRM5 | |
| SCHEMBL31158095 | 0.88 | CHRM3 (0.42) | CHRM2CHRM4CHRM3CHRM1CHRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260115261-A1 | COLLAGEN PEPTIDE-BASED MEDICAMENT COMPOSITIONS AND USES THEREOF | SUSTAIN HOLDINGS LLC (US) | 2026-04-30 | — | — | US | disclosed |
| US-11433112-B1 | Collagen peptide-based medicament compositions and devices and methods of production and use thereof | SUSTAIN HOLDINGS, LLC (US) | 2022-09-06 | — | — | US | disclosed |
| US-11426440-B2 | Collagen peptide-based medicament compositions and devices and methods of production and use thereof | SUSTAIN HOLDINGS, LLC (US) | 2022-08-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260115261-A1 | COLLAGEN PEPTIDE-BASED MEDICAMENT COMPOSITIONS AND USES THEREOF | COL1A1, COL2A1, COL14A1 | CHRM2 2161/4885CHRM4 1458/4885CHRM3 1394/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.